Cutaneous Melanoma

DrugDrug NameDrug Description
DB06186IpilimumabIpilimumab is a monoclonal antibody, more specifically a fully humanized IgG1 antibody produced in mammalian cell culture, to the cytotoxic T lymphocyte antigen-4 (CTLA-4) which activates antitumor immunity by inhibiting this major checkpoint.[A35065, A35080] This antineoplastic agent was developed by Bristol-Myers Squibb and Medarex and FDA approved on March 25, 2011, for the treatment of melanoma.[L3581] On October 2015, the FDA approved expanded the indications for Ipilimumab, allowing it to be used to reduce the risk of relapsed skin cancer after surgery.[L3582] On July 11, 2018, the FDA approved an additional indication for the combination of low dose ipilimumab and [nivolumab] for the treatment of previously treated microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR) metastatic colorectal cancer.[L3590]
DrugDrug NamePhaseStatusCount
DB12001Abemaciclib1Recruiting1
DB12381Merestinib1Recruiting1
DB12821Perflubutane1Recruiting1
DB05578Ramucirumab1Recruiting1
DB09035Nivolumab1 / 2Recruiting1
DB09037Pembrolizumab1 / 2Recruiting1
DB06643Denosumab2Recruiting1
DB12797Ecromeximab2Completed1
DB00105Interferon alfa-2b2Completed1
DB06186Ipilimumab2Recruiting1
DB09035Nivolumab2Recruiting2
DB09037Pembrolizumab2Not Yet Recruiting1
DB09037Pembrolizumab2Recruiting1
DB15185Rasdegafusp alfa2Suspended1
DB14851Relatlimab2Recruiting1
DB13896Talimogene laherparepvec2Not Yet Recruiting1
DB05531alpha-Pyrrolidinononanophenone3Active Not Recruiting1
DB00281LidocaineNot AvailableActive Not Recruiting1
DB01042MelphalanNot AvailableNo Longer Available1